Takeda Pharmaceuticals (TAK +1%) exercises its option to buy
PvP Biologics following the conclusion of a Phase 1 study of
investigational medicine TAK-062 for the treatment of uncontrolled
celiac disease.
Takeda says it will pay an undisclosed upfront fee as well as development and regulatory milestones totaling as much as $330M.
Takeda sees TAK-062 as a potential best-in-class
super glutenase – a protein that degrades ingested gluten – that was
computationally engineered to treat celiac disease, a serious autoimmune
disease where the ingestion of gluten leads to inflammation and damage
in the small intestine.
Full details of the phase 1 data that convinced Takeda to buy PvP are scheduled to be presented at an upcoming medical congress.
https://seekingalpha.com/news/3545854-takeda-to-buy-pvp-biologics-in-330m-deal-after-takminus-062-phase-1-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.